T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers

Autor: Traci Legere, Pradeep B. J. Reddy, Korey A. Walter, Bali Pulendran, Prabhu S. Arunachalam, Shankar Subramaniam, Florian Wimmers, Madeleine K D Scott, Celia C. LaBranche, Bertrand Z. Yeung, John P. Vasilakos, Venkata S. Bollimpelli, Samantha L. Burton, Sailaja Gangadhara, Sudhir Pai Kasturi, Shakti Gupta, Cynthia A. Derdeyn, Caroline Petitdemange, Pamela A. Kozlowski, David C. Montefiori, Tiffany M. Styles, Thomas J. Ketas, John P. Moore, Chil Yong Kang, Rama Rao Amara, Eric Hunter, George M. Shaw, Purvesh Khatri, Mark A. Tomai, Anthony Tsai, David Masopust, Vineet Joag, Clare F. Quarnstrom, Tysheena P. Charles
Rok vydání: 2020
Předmět:
Zdroj: Nature Medicine
ISSN: 1546-170X
1078-8956
DOI: 10.1038/s41591-020-0858-8
Popis: Recent efforts toward an HIV vaccine focus on inducing broadly neutralizing antibodies, but eliciting both neutralizing antibodies (nAbs) and cellular responses may be superior. Here, we immunized macaques with an HIV envelope trimer, either alone to induce nAbs, or together with a heterologous viral vector regimen to elicit nAbs and cellular immunity, including CD8+ tissue-resident memory T cells. After ten vaginal challenges with autologous virus, protection was observed in both vaccine groups at 53.3% and 66.7%, respectively. A nAb titer >300 was generally associated with protection but in the heterologous viral vector + nAb group, titers
An HIV vaccine that elicits both antibodies and cellular immune responses confers long-lasting protection against viral challenge in nonhuman primates.
Databáze: OpenAIRE
Externí odkaz: